Post-approval studies (Phase 4)Study completedNCT00242736
What this trial is testing
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
Who this might be right for
GERD
AstraZeneca 350